Showing 1 - 20 results of 237 for search '"liver cancer"', query time: 0.08s Refine Results
  1. 1

    Epidemiology of Liver Cancer in Europe by F Xavier Bosch, Josepa Ribes

    Published 2000-01-01
    “…Liver cancer (LC) ranks fifth in frequency in the world, with an estimated 437,000 new cases in 1990. …”
    Get full text
    Article
  2. 2

    Genomic Profiling of Liver Cancer by Ju-Seog Lee

    Published 2013-12-01
    “…Development of liver cancers is driven largely by genomic alterations that deregulate signaling pathways, influencing growth and survival of cancer cells. …”
    Get full text
    Article
  3. 3
  4. 4

    Preclinical advance in nanoliposome-mediated photothermal therapy in liver cancer by Lixuan Tang, Xiao Yang, Liwen He, Chaogeng Zhu, Qingshan Chen

    Published 2025-01-01
    “…Abstract Liver cancer is a highly lethal malignant tumor with a high incidence worldwide. …”
    Get full text
    Article
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    Study on the Application of Doxorubicin-Loaded Magnetic Nanodrugs in Targeted Therapy of Liver Cancer by Lei Wang, Liping Liang, Shuzhen Shi, Chao Wang

    Published 2022-01-01
    “…The aim of this study was to use the drug carrier dextran/polylactic acid (DEX/PLA) and paramagnetic Fe3O4 to improve the targeting of DOX in liver cancer treatment while reducing its potential organ toxicity. …”
    Get full text
    Article
  10. 10

    Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment by Jiarui Lv, Yanan Wang, Jiacheng Lv, Cuiting Zheng, Xinyu Zhang, Linyan Wan, Jiayang Zhang, Fangming Liu, Hongbing Zhang

    Published 2025-01-01
    “…Abstract TSC2, a suppressor of mTOR, is inactivated in up to 20% of HBV-associated liver cancer. This subtype of liver cancer is associated with aggressive behavior and early recurrence after hepatectomy. …”
    Get full text
    Article
  11. 11

    Proteomic Characterization of Liver Cancer Cells Treated with Clinical Targeted Drugs for Hepatocellular Carcinoma by Hezhou Long, Jiafu Zhou, Changxia Zhou, Shuyu Xie, Jingling Wang, Minjia Tan, Junyu Xu

    Published 2025-01-01
    “…<b>Results</b>: Utilizing KEGG pathway enrichment analysis, biological process enrichment analysis, and protein interaction network analysis, we elucidated the common and specific metabolic pathways, biological processes, and protein interaction regulatory networks influenced by three liver cancer therapeutics. The study additionally proposed potential combinational treatment strategies, highlighting a possible synergistic interaction between HCC-targeted drugs and the DNA methyltransferase inhibitor. …”
    Get full text
    Article
  12. 12

    Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer by Jiabing Wang, Haoqian Xu, Ying Wang, Long Feng, Fengming Yi

    Published 2023-01-01
    “…We aim to evaluate the efficacy and safety of DEB-TACE in treating primary or secondary liver cancer. Methods. We retrospectively evaluated 59 patients with hepatic malignancies, including 41 patients with primary liver cancer and 18 patients with secondary liver cancer, between September 2016 and February 2019. …”
    Get full text
    Article
  13. 13

    Increased Porphyrins in Primary Liver Cancer Mainly Reflect a Parallel Liver Disease by Jerzy Kaczynski, Göran Hansson, Sven Wallerstedt

    Published 2009-01-01
    “…Hepatic porphyries have been associated with an increased risk of primary liver cancer (PLC), which on the other hand may cause an increased porphyrin production. …”
    Get full text
    Article
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20